As of 11/16/2020, Emgality has the best-in-class* commercial access for the preventive treatment of migraine1,2

*Best-in-class commercial access indicates the subcutaneous CGRP antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial plans for the preventive treatment of migraine.2 Does not take into consideration any restrictions set forth by individual plans. Data as of 11/2020.

Coverage image
Have questions about Emgality? Call us at 1-833-EMGALITY (1-833-364-2548)

Source: Managed Markets Insight & Technology (MMIT), LLC as of 11/2020 and is subject to change without notice. Please contact the plan or state for the most current information. For commercial insurance and Medicare Part D percentages, please contact the plan or state for the most current information. For Medicaid percentage, please refer to the state’s publicly available PDL for the most current information.

“Coverage” includes all statuses at or equivalent to Preferred, Covered, Specialty, or Generic for the preventive treatment of migraine.

“Preferred” refers to product listing on state’s publicly available PDL.

This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.

Employers and employer groups may also offer additional benefit designs, which may be different than described.

For your eligible, commercially insured patients with migraine or episodic cluster headache,

Get your patients started on Emgality: 1 savings cardb for 2 headache conditions3

Patients can get Emgality for as little as $0 for up to 12 months

Savings program image

Help patients save with the Emgality Savings Cardb

bTerms and Conditions: Offer good until 12/31/2021 for up to 12 months of Emgality. Patients with commercial drug insurance may be able to pay as little as $0 for their first fill of Emgality. For the second and subsequent fills, patients must have coverage for Emgality through their commercial drug insurance plan to continue to pay as little as $0 per fill. Offer subject to a monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual savings. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

PA=prior authorization.

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Migraine documents icon

Migraine resources

Emgality Loading Dose Kit (sample)d
The Loading Dose Kit (sample) provides patients with migraine a chance to administer the first monthly dose of Emgality (2 x 120 mg) in their doctor’s office. Loading Dose Kits (samples) are intended to assess tolerability and efficacy for individual patients in the office.

If interested in requesting Emgality 240 mg Loading Dose Kits (samples), please complete and submit your request electronically:

Sample/Sales Representative Request Form

Migraine Patient Questionnaire

Migraine Example Letter of Medical Necessity

Migraine Example Appeal Letter

dSamples are not available for episodic cluster headache.

Learn more

Register here to receive updates from Lilly.

References: 1. Data on File. Lilly USA, LLC. DOF-GZ-US-0114. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0111.

Indications and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.